Background Epidemiologic studies have shown a relationship betweenglycated hemoglobin levels and cardiovascular events in patientswith type 2 diabetes. We investigated whether intensive therapyto target normal glycated hemoglobin levels would reduce cardiovascularevents in patients with type 2 diabetes who had either establishedcardiovascular disease or additional cardiovascular risk factors.
Methods In this randomized study, 10,251 patients (mean age,62.2 years) with a median glycated hemoglobin level of 8.1%were assigned to receive intensive therapy (targeting a glycatedhemoglobin level below 6.0%) or standard therapy (targetinga level from 7.0 to 7.9%). Of these patients, 38% were women,and 35% had had a previous cardiovascular event. The primaryoutcome was a composite of nonfatal myocardial infarction, nonfatalstroke, or death from cardiovascular causes. The finding ofhigher mortality in the intensive-therapy group led to a discontinuationof intensive therapy after a mean of 3.5 years of follow-up.
Results At 1 year, stable median glycated hemoglobin levelsof 6.4% and 7.5% were achieved in the intensive-therapy groupand the standard-therapy group, respectively. During follow-up,the primary outcome occurred in 352 patients in the intensive-therapygroup, as compared with 371 in the standard-therapy group (hazardratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16).At the same time, 257 patients in the intensive-therapy groupdied, as compared with 203 patients in the standard-therapygroup (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemiarequiring assistance and weight gain of more than 10 kg weremore frequent in the intensive-therapy group (P<0.001).
Conclusions As compared with standard therapy, the use of intensivetherapy to target normal glycated hemoglobin levels for 3.5years increased mortality and did not significantly reduce majorcardiovascular events. These findings identify a previouslyunrecognized harm of intensive glucose lowering in high-riskpatients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620
[ClinicalTrials.gov]
.)
Source Information
The members of the writing group (Hertzel C. Gerstein, M.D., M.Sc., McMaster University and Hamilton Health Sciences, Population Health Research Institute, Hamilton, ON, Canada; Michael E. Miller, Ph.D., Robert P. Byington, Ph.D., and David C. Goff, Jr., M.D., Ph.D., Wake Forest University School of Medicine, Winston-Salem, NC; J. Thomas Bigger, M.D., Columbia University College of Physicians and Surgeons, New York; John B. Buse, M.D., Ph.D., University of North Carolina School of Medicine, Chapel Hill; William C. Cushman, M.D., Memphis Veterans Affairs Medical Center, Memphis, TN; Saul Genuth, M.D., and Faramarz Ismail-Beigi, M.D., Ph.D., Case Western Reserve University, Cleveland; Richard H. Grimm, Jr., M.D., Ph.D., Berman Center for Outcomes and Clinical Research, Minneapolis; Jeffrey L. Probstfield, M.D., University of Washington, Seattle; Denise G. Simons-Morton, M.D., Ph.D., National Heart, Lung, and Blood Institute, Bethesda, MD; and William T. Friedewald, M.D., Columbia University Mailman School of Public Health, New York) assume responsibility for the overall content and integrity of this article. This article (10.1056/NEJMoa0802743) was published at www.nejm.org on June 6, 2008.
Address reprint requests to Dr. Byington at the Division of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, or at bbyingto{at}wfubmc.edu.
Intensive Glucose Control in Type 2 Diabetes
Jenny-Avital E. R., Luan F. L., Nguyen K., Tobey T. A., Parashar A., Byington R. P., Gerstein H. C., Friedewald W. T., Patel A., MacMahon S., Chalmers J.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1519-1521, Oct 2, 2008.
Correspondence
This article has been cited by other articles:
Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A.
(2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol
161: 1-9
[Abstract][Full Text]
Lund, S. S., Vaag, A. A.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association: Response to Skyler et al.. Diabetes Care
32: e90-e91
[Full Text]
van Biesen, W., Van Laecke, S., Vanholder, R.
(2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant
24: 2286-2287
[Full Text]
Morath, C., Zeier, M.
(2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant
24: 2026-2029
[Full Text]
Fonseca, V., Inzucchi, S. E., Ferrannini, E.
(2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care
32: 1344-1345
[Full Text]
Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium,
(2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc.
16: 446-456
[Abstract][Full Text]
Cefalu, W. T.
(2009). Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?. Diabetes
58: 1469-1470
[Full Text]
Despres, J.-P.
(2009). Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk. Heart
95: 1118-1124
[Full Text]
Kazempour-Ardebili, S., Lecamwasam, V. L., Dassanyake, T., Frankel, A. H., Tam, F. W.K., Dornhorst, A., Frost, G., Turner, J. J.O.
(2009). Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care
32: 1137-1142
[Abstract][Full Text]
Nauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M., Balena, R.
(2009). Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. Diabetes Care
32: 1237-1243
[Abstract][Full Text]
Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., Rocchini, A., on behalf of the American Heart Association Exerci,
(2009). Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association. Circulation
119: 3244-3262
[Full Text]
Pogach, L. M.
(2009). Pharmacoepidemiology of insulin initiation in diabetes care. CMAJ
180: 1287-1288
[Full Text]
Allen, L. A., Hernandez, A. F., O'Connor, C. M., Felker, G. M.
(2009). End points for clinical trials in acute heart failure syndromes.. J Am Coll Cardiol
53: 2248-2258
[Abstract][Full Text]
The BARI 2D Study Group,
(2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM
360: 2503-2515
[Abstract][Full Text]
Comi, R. J.
(2009). Glucose Control in the Intensive Care Unit: A Roller Coaster Ride or a Swinging Pendulum?. ANN INTERN MED
150: 809-811
[Abstract][Full Text]
Montori, V. M., Fernandez-Balsells, M.
(2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED
150: 803-808
[Abstract][Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp
55: 580-582
[Full Text]
Wilson, G., Perry, T.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: NO. cfp
55: 581-583
[Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp
55: 584-588
[Full Text]
Wilson, G., Perry, T.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: NON. cfp
55: 585-588
[Full Text]
Nahas, R., Moher, M.
(2009). Complementary and alternative medicine for the treatment of type 2 diabetes. cfp
55: 591-596
[Abstract][Full Text]
Haynes, R B., Haynes, G. A
(2009). What does it take to put an ugly fact through the heart of a beautiful hypothesis?. Evid. Based Med.
14: 68-69
[Full Text]
Booth, G. L
(2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med.
14: 73-73
[Full Text]
Diener, H.-C., Weimar, C.
(2009). Update of secondary stroke prevention. Nephrol Dial Transplant
24: 1718-1724
[Full Text]
McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., Herman, W. H.
(2009). Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD). Diabetes Care
32: 971-976
[Abstract][Full Text]
Catalano, P. M., Presley, L., Minium, J., Hauguel-de Mouzon, S.
(2009). Fetuses of Obese Mothers Develop Insulin Resistance in Utero. Diabetes Care
32: 1076-1080
[Abstract][Full Text]
Buse, J. B., Wolffenbuttel, B. H.R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., Martin, S. A.
(2009). DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care
32: 1007-1013
[Abstract][Full Text]
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., Fink, J. C.
(2009). Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. CJASN
4: 1121-1127
[Abstract][Full Text]
Goode, K M, John, J, Rigby, A S, Kilpatrick, E S, Atkin, S L, Bragadeesh, T, Clark, A L, Cleland, J G F
(2009). Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart
95: 917-923
[Abstract][Full Text]
Hall, G. M., Nicholson, G.
(2009). Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesth. Analg.
108: 1727-1730
[Full Text]
Griffin, S., Graffy, J.
(2009). New QOF glycaemia targets are achievable and evidence based. BMJ
338: b1915-b1915
[Full Text]
Banarer, S., Luan, F. L., Duckworth, W. C., Moritz, T., Abraira, C.
(2009). Glucose Control and Vascular Complications in Type 2 Diabetes. NEJM
360: 2031-2032
[Full Text]
Matfin, G.
(2009). Diabetes P4P: a view from near and far. British Journal of Diabetes & Vascular Disease
9: 96-97
Gellad, W. F., Detsky, A. S., Choudhry, N. K.
(2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm
66: 864-867
[Full Text]
Verhaert, D., Thomas, J. D.
(2009). Dysglycemia and acute myocardial infarction the role of echocardiography.. J Am Coll Cardiol Img
2: 600-603
[Full Text]
Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A.
(2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant
24: 1663-1671
[Abstract][Full Text]
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A.
(2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes
58: 1229-1236
[Abstract][Full Text]
Doucette, W. R, Witry, M. J, Farris, K. B, McDonough, R. P
(2009). Community Pharmacist-Provided Extended Diabetes Care. The Annals of Pharmacotherapy
43: 882-889
[Abstract][Full Text]
Brice, R.
(2009). A taxi driver with type 2 diabetes. BMJ
338: b1369-b1369
[Full Text]
Cheng, A. Y.Y., Leiter, L. A.
(2009). Cardiovascular risk and glycemic control. CMAJ
180: 907-908
[Full Text]
Ko, G. T.C., So, W.-Y., Tong, P. C., Chan, W.-B., Yang, X., Ma, R. C., Kong, A. P., Ozaki, R., Yeung, C.-Y., Chow, C.-C., Chan, J. C.
(2009). Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ
180: 919-926
[Abstract][Full Text]
Riveline, J.-P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., Hadjadj, S.
(2009). Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant
0: gfp181v1-gfp181
[Abstract][Full Text]
Fanestil, B. D.
(2009). The Tyranny of the Measuring Cup. JAMA
301: 1515-1516
[Full Text]
Young, L. H., Wackers, F. J. Th., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., Ratner, R. E., Inzucchi, S. E., for the DIAD Investigators,
(2009). Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial. JAMA
301: 1547-1555
[Abstract][Full Text]
Kahn, S. E.
(2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA
301: 1590-1592
[Full Text]
Nathan, D. M.
(2009). Progress in Diabetes Research--What's Next. JAMA
301: 1599-1601
[Full Text]
Van den Berghe, G., Mesotten, D., Vanhorebeek, I.
(2009). Intensive insulin therapy in the intensive care unit. CMAJ
180: 799-800
[Full Text]
Preis, S. R., Hwang, S.-J., Coady, S., Pencina, M. J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S.
(2009). Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. Circulation
119: 1728-1735
[Abstract][Full Text]
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Med.
14: 34-37
[Full Text]
Cochran, E.
(2009). U-500 Insulin: When More With Less Yields Success. Diabetes Spectr.
22: 116-122
[Full Text]
O'Connor, P. J., Sperl-Hillen, J. M.
(2009). The Role of Diabetes Educators in the Medical Home. Diabetes Spectr.
22: 124-126
[Full Text]
Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D.
(2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice
22: 179-193
[Abstract]
Nuzum, D. S., Merz, T.
(2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice
22: 135-148
[Abstract]
Younis, N., Soran, H., Hassanein, M.
(2009). Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM
102: 293-296
[Full Text]
van Schothorst, E. M., Bunschoten, A., Schrauwen, P., Mensink, R. P., Keijer, J.
(2009). Effects of a high-fat, low- versus high-glycemic index diet: retardation of insulin resistance involves adipose tissue modulation. FASEB J.
23: 1092-1101
[Abstract][Full Text]
Chait, A., Bornfeldt, K. E.
(2009). Diabetes and atherosclerosis: is there a role for hyperglycemia?. J. Lipid Res.
50: S335-S339
[Abstract][Full Text]
Inzucchi, S. E., Siegel, M. D.
(2009). Glucose Control in the ICU -- How Tight Is Too Tight?. NEJM
360: 1346-1349
[Full Text]
The NICE-SUGAR Study Investigators,
(2009). Intensive versus Conventional Glucose Control in Critically Ill Patients. NEJM
360: 1283-1297
[Abstract][Full Text]
Lauer, M. S.
(2009). Comparative Effectiveness Research: The View From the NHLBI. J Am Coll Cardiol
53: 1084-1086
[Full Text]
Kosiborod, M., Inzucchi, S. E., Krumholz, H. M., Masoudi, F. A., Goyal, A., Xiao, L., Jones, P. G., Fiske, S., Spertus, J. A.
(2009). Glucose Normalization and Outcomes in Patients With Acute Myocardial Infarction. Arch Intern Med
169: 438-446
[Abstract][Full Text]
Lehman, R., Krumholz, H. M
(2009). Tight control of blood glucose in long standing type 2 diabetes. BMJ
338: b800-b800
[Full Text]
Fraser, A. G.
(2009). Echocardiographic epidemiology--an emerging tool for early diagnosis, studying pathophysiology, predicting prognosis, and testing treatments. Eur Heart J
30: 642-644
[Full Text]
Song, S. H, Gray, T. A
(2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease
9: 69-74
[Abstract]
Henske, J. A., Griffith, M. L., Fowler, M. J.
(2009). Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Clin. Diabetes
27: 72-76
[Full Text]
Raz, I., Wilson, P. W.F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., Jacober, S. J.
(2009). Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care
32: 381-386
[Abstract][Full Text]
Ceriello, A.
(2009). Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?. Diabetes Care
32: 521-522
[Full Text]
Woo, V., for the CDA 2008 Clinical Practice Guidelines Stee,
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. . Diabetes Care
32: e34-e34
[Full Text]
Nathan, D. M., for the ADA/EASD Consensus Committee,
(2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Woo and Eizirik . Diabetes Care
32: e37-e38
[Full Text]
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., Service, F. J.
(2009). Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab.
94: 709-728
[Abstract][Full Text]
Davis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., Tate, D. B.
(2009). Effects of Intensive Therapy and Antecedent Hypoglycemia on Counterregulatory Responses to Hypoglycemia in Type 2 Diabetes. Diabetes
58: 701-709
[Abstract][Full Text]
Launer, L. J.
(2009). Diabetes: Vascular or Neurodegenerative: An Epidemiologic Perspective. Stroke
40: S53-S55
[Full Text]
Kassabian, S. G.
(2009). Hemoglobin A1c Testing, Board-Recertification Scores, and Treatment Outcomes. Arch Intern Med
169: 417-417
[Full Text]
Holmboe, E. S., Wang, Y., Meehan, T. P., Tate, J. P., Ho, S.-Y., Lipner, R. S.
(2009). Is Quality of Care Only Instrumental?--Reply. Arch Intern Med
169: 418-418
[Full Text]
Cleland, J. G.F., Tavazzi, L., Daubert, J.-C., Tageldien, A., Freemantle, N.
(2009). Cardiac resynchronization therapy are modern myths preventing appropriate use?. J Am Coll Cardiol
53: 608-611
[Full Text]
Gerstein, H. C.
(2009). Dysglycemia and Cardiovascular Risk in the General Population. Circulation
119: 773-775
[Full Text]
Liew, G., Mitchell, P., Wong, T. Y
(2009). Systemic management of diabetic retinopathy. BMJ
338: b441-b441
[Full Text]
Horton, E. S.
(2009). Defining the role of basal and prandial insulin for optimal glycemic control.. J Am Coll Cardiol
53: S21-S27
[Abstract][Full Text]
NAJMAN, D. M.
(2009). Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008). Cleveland Clinic Journal of Medicine
76: 83-83
[Full Text]
O'Sullivan, E. P, Dinneen, S. F
(2009). Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years. Evid. Based Med.
14: 9-10
[Full Text]
HOOGWERF, B. J.
(2009). IN REPLY:. Cleveland Clinic Journal of Medicine
76: 83-84
[Full Text]
Ceriello, A., Ihnat, M. A., Thorpe, J. E.
(2009). The "Metabolic Memory": Is More Than Just Tight Glucose Control Necessary to Prevent Diabetic Complications?. J. Clin. Endocrinol. Metab.
94: 410-415
[Abstract][Full Text]
Eddy, D., Schlessinger, L., Kahn, R., Peskin, B., Schiebinger, R.
(2009). Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis. Diabetes Care
32: 361-366
[Abstract][Full Text]
Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., Freeman, R.
(2009). Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function: Implications for Rigorous Glycemic Control. Diabetes
58: 360-366
[Abstract][Full Text]
Khanderia, U., Pop-Busui, R., Eagle, K.
(2009). Authors' Reply. The Annals of Pharmacotherapy
43: 392-393
[Full Text]
Havas, S.
(2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med
169: 150-154
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol
53: 298-304
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation
119: 351-357
[Full Text]
Aron, D., Pogach, L.
(2009). Transparency Standards for Diabetes Performance Measures. JAMA
301: 210-212
[Full Text]
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., the VADT Investigators,
(2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM
360: 129-139
[Abstract][Full Text]
Previous
